Autolus Therapeutics to Participate in Investor Conferences Through April

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1’s at investor conferences through April 2021.

Read the original:
Autolus Therapeutics to Participate in Investor Conferences Through April

Related Posts